US Patent No: 7,846,725

Number of patents in Portfolio can not be more than 2000

Antibody composition-producing cell in which enzyme expression is inhibited by RNAi

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
KYOWA HAKKO KIRIN CO., LTD.TOKYO273

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hanai, Nobuo Machida, JP 94 1588
Hosaka, Emi Machida, JP 45 1044
Kanda, Yutaka Machida, JP 78 1326
Nakamura, Kazuyasu Machida, JP 80 1374
Satoh, Mitsuo Machida, JP 51 961
Shinkawa, Toyohide Machida, JP 35 1078
Uchida, Kazuhisa Machida, JP 46 1155
Yamane, Naoko Machida, JP 35 1004
Yamano, Kazuya Machida, JP 39 706
Yamasaki, Motoo Machida, JP 86 1327

Cited Art Landscape

Patent Info (Count) # Cites Year
 
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (1)
6,238,894 .alpha.1,2 fucosyltransferase 27 1999
 
PANASONIC CORPORATION OF NORTH AMERICA (2)
7,687,061 Method of modulating the activity of functional immune molecules to Her-2 14 2007
2007/0166,305 Method of Modulating the Activity of Functional Immune Molecules 27 2007
 
MARIEL THERAPEUTICS, INC. (1)
5,614,385 Methods and compositions for high protein production from recombinant DNA 33 1995
 
Centro de Inmunologia Molecular (1)
5,891,996 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use 137 1995
 
OSAKA UNIVERSITY (1)
2003/0170,813 Process for producing glycoprotein 29 2003
 
DOVETAIL TECHNOLOGIES INC. (1)
6,762,174 Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof 22 1999
 
GLAXOSMITHKLINE LLC (1)
5,783,184 Method for treatment and diagnosis of IL-5 mediated disorders 16 1996
 
SMITHKLINE BEECHAM P.L.C. (1)
6,129,913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders 27 1997
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,272,070 Method for the preparation of cell lines producing Man.sub.3 GlcN.sub.ac 2 asparagine-linked gylcans and cell lines produced thereby 69 1991
 
GREEN CROSS CORPORATION, THE (1)
4,721,777 Process for the virus-inactivation of immunoglobulin 39 1985
 
MEDAREX, INC. (1)
5,922,845 Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies 106 1996
 
The University of North Carolina at Chapel Hill (1)
6,350,868 Antisense human fucosyltransferase sequences and methods of use thereof 25 2000
 
TOUDAI TLO, LTD. (2)
2004/0002,077 siRNA expression system and method for producing functional gene knock-down cell using the system 71 2002
2005/0048,647 Sirna expression system and process for producing functional gene knockdown cell or the like using the same 59 2004
 
Desmos, Inc. (1)
5,658,789 Promotion of epithelial cell adhesion and hemidesmosome assembly by a laminin-like molecule 30 1995
 
UNIVERSITY OF UTAH (1)
5,464,764 Positive-negative selection methods and vectors 264 1993
 
University of Kentucky Research Foundation (2)
5,977,316 Monoclonal antibody 1A7 and related polypeptides 32 1996
5,935,821 Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma 48 1996
 
WISTAR INSTITUTE, THE, A CORP OF PA (1)
4,849,509 Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies 52 1987
 
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY (1)
6,540,980 Method of detecting endometriosis 29 2000
 
Hazleton Biotechnologies, Inc. (1)
4,757,018 Myeloma cell lines and uses thereof 30 1985
 
ROCHE GLYCART AG (5)
6,602,684 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 159 1999
2004/0072,290 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 68 2003
2005/0074,843 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 49 2003
2005/0079,605 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 45 2003
2007/0111,281 Antigen binding molecules having modified Fc regions and altered binding to Fc receptors 39 2006
 
THERMO FISHER SCIENTIFIC INC. (1)
2007/0031,844 Functional and hyperfunctional siRNA 408 2003
 
ACTIVCARD IRELAND LIMITED (1)
7,502,497 Method and system for extracting an area of interest from within an image of a biological surface 20 2007
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
6,488,930 Anti-CCR4 antibodies and methods of use therefor 36 1999
7,138,117 Anti-CCR4 antibodies and methods of use therefor 24 2002
 
ICOS Corporation (3)
5,880,268 Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18 36 1995
5,932,703 Macrophage derived chemokine and chemokine analogs 37 1996
6,498,015 Methods of identifying agents that modulate the binding between MDC and an MDC receptor 32 1997
 
The General Hospital Corporation (1)
5,858,983 Inhibition of cell adhesion protein-carbohydrate interactions 44 1995
 
FUJITSU LIMITED (1)
6,189,781 Terminal unit having function for converting commodity information into bar code and vice versa 32 1994
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
2003/0190,316 Stabilized antibody-containing preparations 87 2003
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
4,350,683 Antibody production from hybrid cell line 84 1980
 
GLAXO GROUP LIMITED (1)
6,150,132 Chemokine receptor able to bind to MCP-1, MIP-1.alpha. and/or RANTES. Its uses 42 1997
 
KYOWA HAKKO KOGYO CO., LTD. (5)
2004/0093,621 Antibody composition which specifically binds to CD20 101 2002
2004/0110,704 Cells of which genome is modified 69 2003
2005/0160,485 Mouse in which genome is modified 23 2004
2005/0226,867 IL-5R-specific antibody composition 24 2004
2005/0287,138 CCR4-specific antibody composition 25 2004
 
LEUKOSITE, INC. (1)
6,245,332 Modulation of systemic memory T cell trafficking 32 1999
 
KYOWA HAKKO KIRIN CO., LTD. (36)
5,830,470 Humanized antibodies to ganglioside GM.sub.2 50 1993
6,018,032 Antibody against human interleukin-5-receptor .alpha. chain 42 1997
6,437,098 Human chimeric antibody specific for the ganglioside GD3 27 1999
6,986,890 Anti-human VEGF receptor Flt-1 monoclonal antibody 44 1999
6,989,145 Recombinant antibody and antibody fragment 38 2001
6,946,292 Cells producing antibody compositions with increased antibody dependent cytotoxic activity 109 2001
2003/0175,273 Human CDR-grafted antibody and antibody fragment thereof 33 2002
7,691,568 Antibody composition-containing medicament 13 2003
2004/0110,282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost 48 2003
2004/0132,140 Production process for antibody composition 99 2003
7,691,810 Method of producing recombinant antithrombin III composition 11 2004
2005/0187,380 Method for treating Th2-mediated disease 23 2005
7,214,775 Method of modulating the activity of functional immune molecules 75 2005
7,708,992 Methods for producing antibody compositions with increased ADCC 19 2005
2005/0272,916 Method of modulating the activity of functional immune molecules 38 2005
2006/0024,800 Method of modulating the activity of functional immune molecules 31 2005
2005/0216,958 Cells of which genome is modified 27 2005
2005/0262,593 Antibody composition-producing cell 29 2005
2006/0223,147 Process for producing glycoprotein composition 32 2005
2006/0063,254 Antibody composition-producing cell 37 2005
2006/0064,781 Antibody composition-producing cell 36 2005
7,393,683 Mammalian host cell modified by RNAi to inhibit .alpha. 1,6-fucosyltransferase 21 2005
7,425,446 Antibody composition-producing cell 24 2005
7,709,234 α-1,3-fucosyltransferase 12 2006
2007/0148,165 Recombinant antibody composition 22 2006
7,651,688 Method of modulating the activity of functional immune molecules to CD52 17 2007
7,655,228 Method of modulating the activity of functional immune molecules to GM2 14 2007
7,682,610 Method of modulating the activity of functional immune molecules 14 2007
7,682,611 Method of modulating the activity of functional immune molecules to CXCR4 protein 14 2007
7,708,997 Method of modulating the activity of functional immune molecules 14 2007
2007/0166,300 Method of Modulating the Activity of Functional Immune Molecules 26 2007
2007/0166,301 Method of Modulating the Activity of Functional Immune Molecules 26 2007
2007/0166,302 Method of Modulating the Activity of Functional Immune Molecules 26 2007
2007/0166,303 Method of Modulating the Activity of Functional Immune Molecules 26 2007
2007/0166,304 Method of Modulating the Activity of Functional Immune Molecules 26 2007
2008/0261,301 Antibody Composition-Producing Cell 24 2008
 
TANIGUCHI, NAOYUKI (2)
6,054,304 .alpha.1-6 fucosyltransferase 49 1998
6,291,219 .alpha.1-6 fucosyltransferase 23 1999
 
BIOGEN IDEC MA INC. (1)
7,033,589 γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics 25 1999
 
GENENEWS INC. (1)
2005/0208,519 Biomarkers for diagnosing schizophrenia and bipolar disorder 16 2004
 
Genentech, Inc. (4)
4,816,567 Recombinant immunoglobin preparations 2116 1983
6,169,070 Mer receptor activation by gas6 76 1996
6,737,056 Polypeptide variants with altered effector function 332 2000
7,297,775 Polypeptide variants 48 2002
 
BIOGEN, INC. (1)
6,455,043 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody 103 1999
 
Takatsu; Kiyoshi (1)
5,916,767 DNA encoding human interleukin-5 receptor 13 1997
 
SRD PHARMACEUTICALS, INC. (1)
5,665,569 HIV immunotherapeutics 41 1994
 
BOEHRINGER MANNHEIM GMBH (1)
5,453,363 Process for the activation of t-PA or Ing after genetic expression in prokaryotes 36 1994
 
LONZA GROUP, AG (1)
5,672,502 Animal cell culture 77 1995
 
GENETICS INSTITUTE, LLC (1)
5,728,568 Human GDP-mannose 4,6 dehydratase 31 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BIOWA, INC. (1)
8,501,176 Methods of reducing eosinophil levels 3 2011
 
KYOWA HAKKO KIRIN CO., LTD. (14)
8,067,232 Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase 0 2008
* 2008/0227,196 Antibody Composition-Producing Cell 3 2008
8,158,760 Glycoengineered, recombinant antibody 1 2009
8,039,595 Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation 4 2009
8,367,407 Cells with altered fucosylation and producing antibodies therefrom 0 2009
* 2010/0143,388 Antibody Composition-Producing Cell 2 2009
8,679,491 Method of modulating the activity of functional immune molecules 1 2009
* 2011/0027,271 ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION 2 2010
8,110,195 Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody 1 2010
* 8,101,185 Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation 1 2010
* 8,329,443 Antibody composition-producing cell 0 2011
* 2011/0250,643 ANTIBODY COMPOSITION-PRODUCING CELL 4 2011
8,895,266 Antibody composition-producing cell 0 2012
9,409,982 Antibody composition-producing cell 0 2014
 
ASTRAZENECA AB (3)
9,441,037 Methods for reducing exacerbation rates of asthma using benralizumab 0 2014
9,441,046 Methods for increasing forced expiratory volume in asthmatics using benralizumab 0 2014
9,441,047 Methods for improving asthma symptoms using benralizumab 0 2014
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 7, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 7, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00